From June 2017 to December 2018, Mr. Pang Yunlong from Dentons Xiamen office, together with his team members lawyer Chen Yi and Wu Qin, advised Encheng Group Co., Ltd., a company that specializes in medical services and precision medical industry, on introducing revolutionary cancer precision treatment from the US. After a long period of negotiations and consultations, Encheng Group officially announced the establishment of its strategic partnership with Darwin Health Company, which was founded by Andrea Califano, academician of the American Academy of Medical Sciences and professor of Columbia University In December 2018. Encheng Group has the exclusive license of the New York State Department of Health's CLIA-certified DarwinOncoTargetTM and DarwinOncoTreatTM tests that gives it the right to set up, use and conduct these tests in China.
The "DarwinOncoTarget/DarwinOncoTreat" test and treatment method is the latest major advance in the field of cancer precision therapy. It generates a comprehensive tumor-targeted treatment protocol that reveals indirect but highly precise tumor abnormal protein activity indicators and implied protein interaction networks through the calculation and analysis of whole transcriptome sequencing data (RNASeq) from patient tumor samples to determine the optimal treatment regimen based on different patients. The two world-leading tests mentioned above are expected to be officially put into use in China in May 2019.
As a special legal counsel of Encheng Group, Pang Yunlong's lawyer team provided special legal services such as professional negotiation plan design, negotiation work plan, represented negotiation and special consultation during the consultation process between Encheng Group and Darwin Health Company and also participated in the design and improvement of the transaction structure and risk control mechanism together with American lawyers and Hong Kong lawyers. Pang Yunlong’s team has provided professional and high-quality legal services to the client and has been highly recognized.
As a leading innovator in China's healthcare industry, Xiamen Encheng Group Co., Ltd. integrates drug development, production and sales through its network in China, and conducts long-term strategic cooperation with Chinese cancer authoritative research institutions and renowned academicians at home and abroad. At present, Encheng is actively conducting research on PDX and tumorous body nurture to promote its drug development and clinical services in the field of precision cancer medicine.
PR Newswire Agency original link:
Revolutionary cancer precision therapy introduced to China by academician Califano of the American Academy of Medical Sciences
https://www.prnasia.com/story/233967-1.shtml